Succeeding in developing a next-generation technique for culturing stem cells while enhancing the therapeutic efficacy and production rate, MEDIPOST obtained a patent for the technique in the US.

The title of this patent is ‘Method for culturing mesenchymal stem cells’ and this technique is expected to enhance the level of research and development of stem cell drugs.

An official from MEDIPOST explained, “This patent means that our stem cell culturing technique is recognized across the world. With this technique, we expect to see a growth in our business competence in the American stem cell market.”

Last year, MEDIPOST acquired a total of 18 Korean and international patents and was ranked no.1 in the biopharmaceutical industry according to the stock exchange posting.